DA
Dare Bioscience, Inc.
DARE · NASDAQ
$0.73 -0.89% (-$0.01)
1M -4.96%
Market Cap $10.9M
P/E Ratio -
Div. Yield -
ROE 748.08%
Bulios Fair Price
$1.08
48.9% upside
Current Price
$0.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DARE is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
5 /100
Expensive P/S 7.96x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Rev. growth 53.12%
Book val. growth 36.52%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 89.45%
FCF margin 860.62%
Net margin 804.37%
Quality
1 /100
Poor ROIC 179.10%
Asset turnover 0.06x
ROE 748.08%
Debt
16 /100
High Current ratio 0.99x
Int. coverage -53.95x
Debt/Equity N/A
Stability
23 /100
Unstable Beta 1.01x
Profitable years 0
Rev. volatility 6,070.94%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DARE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sabrina Martucci Johnson
Employees
23
Headquarters
San Diego
Upcoming events
12 NOV
Earnings
Upcoming earnings report